AO Spine at the Spine Summit 2018
06 March 2018
Under the theme of "Restoring alignment in an era of global change", the Spine Summit 2018 promises to be an exciting and thought-provoking exploration of the latest in innovation and neurosurgical education.
One of seven special courses at the Spine Summit 2018 will involve the AO Spine KF Tumor. The "Spinal Tumoral Pathology Made Easy (Diagnosis and Management) with AO Spine" seminar is designed to review the myriad presentations of spinal tumors, and to discuss the multi-disciplinary management options involving medical, radiation, and surgical treatments. The course will enable participants to implement the most appropriate treatment approach for patients with symptomatic metastatic spinal lesions; to explain to patients the differences in morbidity and outcomes between en bloc resection versus surgery plus radiation therapy for primary spinal malignancies; and to select the most appropriate patients for minimally invasive resection of intradural spinal tumors.
Course directors John E. O’Toole and Daniel M. Sciubba will be joined by other KF Tumor members, Charles Fisher, Chetan Bettegowda, Ziya L. Gokaslan, Laurence D. Rhines, Nicolas Dea, Dean Chou, Ilya Laufer, Joseph H. Schwab, John H. Shin, and specialists Claudio E. Tatsui, Michael S. Virk, Ehud Mendel, and Paul C. McCormick.
The Spine Summit 2018 will offer participants an opportunity to collaborate with spine and peripheral nerve surgeons at the forefront of their field, to discover the latest innovations, and to discuss strategies to find balance and direction in a time of rapid and meaningful change in health care.
- Spine Summit 2018 in the theme park destination of Universal Orlando® from 14 – 17 March 2018.
- AOSpine Knowledge Forum Tumor special course 4 "Spinal Tumoral Pathology Made Easy (DX-Management) with AO Spine" on Wednesday, 14 March, from 01:30 pm – 05:30 pm.
To register, click on Spine Summit 2018.
For more information, review the online program book.
More information on AO Spine Knowledge Forum Tumor and their studies.